Larvol Delta - PureTech-Showcases-Differentiated-Development-Strategy-Including-New-Patient-Preference-Insights-and-Spotlights-Phase-2b-Data-Positioning-Deupirfenidone-as-a-Potential-New-Standard-of-Care-in-IPF

deupirfenidone (LYT-100) - PureTech

https://www.businesswire.com/news/home/20250821614975/en/PureTech-Showcases-Differentiated-Development-Strategy-Including-New-Patient-Preference-Insights-and-Spotlights-Phase-2b-Data-Positioning-Deupirfenidone-as-a-Potential-New-Standard-of-Care-in-IPF

Aug 22, 2025

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next